Loading chart…
CLOSED
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development.
Laurus Labs Limited (LAURUSLABS) is listed on the NSE in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. The LAURUSLABS share price is ₹2,437.70 (+4.18% today), with a market capitalisation of ₹1.32T and a price-to-earnings (P/E) ratio of 99.6. MarketRipple tracks the LAURUSLABS investment thesis, the ripple-chain impact of market events on Laurus Labs Limited, and the Healthcare sector outlook.
Open
₹2,351.50
High
₹2,480.00
Low
₹2,351.50
Prev. Close
₹2,340.00
52W High
₹2,441.90
52W Low
₹917.95
Day range
₹2,351.50–₹2,480.00
52-week range
₹917.95–₹2,441.90
Volume
2.5M
P/E
99.6
ROE
24.0%
D/E
0.48
Margin
17.1%
Laurus Labs Limited (NSE: LAURUSLABS) is currently trading at ₹2,437.70 (+4.18%).
Laurus Labs Limited's market capitalization is ₹1.32T.
Laurus Labs Limited's price-to-earnings (P/E) ratio is 99.6.
Laurus Labs Limited operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Analyst consensus on Laurus Labs Limited currently reads neutral, based on 14 analysts covering the stock. This is third-party analyst data, not a MarketRipple recommendation.